Browsing Tag
Cambridge
23 posts
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Akamai stock surges 20% on $1.8bn AI cloud deal: What AKAM investors need to watch next
Wall Street wrote off Akamai as a fading CDN name. One $1.8B cloud deal and 40% Cloud Infrastructure growth just rewrote the entire AKAM thesis overnight.
JuliaHub targets industrial digital twins with $65m Series B and Dyad 3.0 launch
Hardware still moves slowly while software races ahead. JuliaHub’s Dyad 3.0 aims to close that gap with agentic industrial AI.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
British Land (LSE: BLND) to acquire Life Science REIT in £150m science property deal
British Land to acquire Life Science REIT for £150M in a strategic science real estate deal. Find out how this reshapes the UK innovation leasing market.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Genfit abandons VS-01 in ACLF after safety scare—can a pivot to UCD rescue GNFT’s pipeline story?
Genfit ends VS-01 in ACLF and refocuses on UCD, trims spend, and extends runway beyond 2028. Find out what it means for GNFT stock and 2025 catalysts.
Ategenos unveils SmartPatch to tackle $528bn medication non-adherence crisis
Ategenos debuts SmartPatch, a first-of-its-kind connected patch tackling $528bn medication non-adherence with real-time, IoT-enabled monitoring.
Vyome completes merger with ReShape Lifesciences, to debut on Nasdaq as Vyome Holdings (HIND) on August 15
Vyome merges with ReShape Lifesciences, will trade on Nasdaq as Vyome Holdings (HIND) from August 15, focusing on immuno-inflammatory and rare diseases.
Novartis dodges Trump’s drug tariff blitz with $23bn US reshoring plan
Find out how Novartis plans to produce all key medicines in the US through a $23B investment in 10 new and expanded facilities nationwide.